Tammy T. Nguyen
Tammy T. Nguyen has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Andres Schanzer
3 shared publicationsJessica P. Simons
3 shared publications- Areck Ucuzian
VA Maryland Healthcare Syst, Dept Surg, Baltimore, MD USA
2 shared publications - Javier Solivan-Rivera
Program in Molecular Medicine, University of Massachusetts Chan Medical School
2 shared publications - Pantos Skritakis
Program in Molecular Medicine, University of Massachusetts Chan Medical School
2 shared publications - Samantha Danielle Minc
Division of Vascular and Endovascular Surgery, Department of Surgery, Duke University, Durham, North Carolina, USA
2 shared publications
Latest Publications
- Open Access
- 25 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Evaluating Equitable Reach of Social Determinants of Health Screening Using Geospatial Measures of Structural Disadvantage: Rapid Surveillance Report (Preprint)
UNSTRUCTURED Health systems increasingly screen patients for social determinants of health (SDoH) to connect them with supportive services, yet little is known about whether screening initiatives equitably reach communities in proportion to structural disadvantage. This process evaluation examined whether implementation of a health system SDoH screening initiative reached communities experiencing structural disadvantage and identified geographic gaps in screening reach. UMass Memorial Health implemented system-wide SDoH screening across primary care practices using clinic-based workflows and digital tools, including the patient portal and short message service messaging. Electronic health record data from patients with at least one primary care encounter between April 2022 and May 2025 were geocoded to census tracts and linked to the Structural Racism Effect Index (SREI). Multilevel logistic regression models assessed associations between structural disadvantage, screening completion, and reporting of social needs. A composite SDoH screening equity index combining patient catchment size, screening rates, and SREI was developed to visualize geographic variation in screening reach. Higher SREI was associated with greater odds of reporting at least one social need (OR 1.32; 95% CI 1.25–1.41) but was not associated with screening completion (OR 0.97; 95% CI 0.92–1.02). Mapping identified clusters of census tracts with high structural disadvantage but comparatively low screening reach. Geospatial process evaluation can help health systems identify inequities in screening implementation and guide targeted outreach strategies to improve equitable access to health and social care resources.
- 25 June 2026
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEvaluating Equitable Reach of Social Determinants of Health Screening Using Geospatial Measures of Structural Disadvantage: Rapid Surveillance Report (Preprint)
UNSTRUCTURED Health systems increasingly screen patients for social determinants of health (SDoH) to connect them with supportive services, yet little is known about whether screening initiatives equitably reach communities in proportion to structural disadvantage. This process evaluation examined whether implementation of a health system SDoH screening initiative reached communities experiencing structural disadvantage and identified geographic gaps in screening reach. UMass Memorial Health implemented system-wide SDoH screening across primary care practices using clinic-based workflows and digital tools, including the patient portal and short message service messaging. Electronic health record data from patients with at least one primary care encounter between April 2022 and May 2025 were geocoded to census tracts and linked to the Structural Racism Effect Index (SREI). Multilevel logistic regression models assessed associations between structural disadvantage, screening completion, and reporting of social needs. A composite SDoH screening equity index combining patient catchment size, screening rates, and SREI was developed to visualize geographic variation in screening reach. Higher SREI was associated with greater odds of reporting at least one social need (OR 1.32; 95% CI 1.25–1.41) but was not associated with screening completion (OR 0.97; 95% CI 0.92–1.02). Mapping identified clusters of census tracts with high structural disadvantage but comparatively low screening reach. Geospatial process evaluation can help health systems identify inequities in screening implementation and guide targeted outreach strategies to improve equitable access to health and social care resources.
- 17 September 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (1) , 181-189
Utilization of large-scale electronic health record database to understand social determinants of health disparities in the diabetic patient population with major lower extremity amputation
- 17 September 2025
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 83 (1) , 181-189
Utilization of large-scale electronic health record database to understand social determinants of health disparities in the diabetic patient population with major lower extremity amputation
- Open Access
- 27 December 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 3
Utilizing multidisciplinary mobile outreach clinics to provide comprehensive diabetic foot care to patients experiencing homelessness
- 27 December 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 3
Open AccessUtilizing multidisciplinary mobile outreach clinics to provide comprehensive diabetic foot care to patients experiencing homelessness
- Open Access
- 27 July 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
Optimizing ankle-brachial index measurement for peripheral arterial disease screening in mobile clinics
- 27 July 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
Open AccessOptimizing ankle-brachial index measurement for peripheral arterial disease screening in mobile clinics
- Open Access
- 2 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 750
Translational Challenges in Drug Therapy and Delivery Systems for Treating Chronic Lower Extremity Wounds
Despite several promising preclinical studies performed over the past two decades, there remains a paucity of market-approved drugs to treat chronic lower extremity wounds in humans. This translational gap challenges our understanding of human chronic lower extremity wounds and the design of wound treatments. Current targeted drug treatments and delivery systems for lower extremity wounds rely heavily on preclinical animal models meant to mimic human chronic wounds. However, there are several key differences between animal preclinical wound models and the human chronic wound microenvironment, which can impact the design of targeted drug treatments and delivery systems. To explore these differences, this review delves into recent new drug technologies and delivery systems designed to address the chronic wound microenvironment. It also highlights preclinical models used to test drug treatments specific for the wound microenvironments of lower extremity diabetic, venous, ischemic, and burn wounds. We further discuss key differences between preclinical wound models and human chronic wounds that may impact successful translational drug treatment design.
- 2 June 2024
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (6) , 750
Open AccessTranslational Challenges in Drug Therapy and Delivery Systems for Treating Chronic Lower Extremity Wounds
Despite several promising preclinical studies performed over the past two decades, there remains a paucity of market-approved drugs to treat chronic lower extremity wounds in humans. This translational gap challenges our understanding of human chronic lower extremity wounds and the design of wound treatments. Current targeted drug treatments and delivery systems for lower extremity wounds rely heavily on preclinical animal models meant to mimic human chronic wounds. However, there are several key differences between animal preclinical wound models and the human chronic wound microenvironment, which can impact the design of targeted drug treatments and delivery systems. To explore these differences, this review delves into recent new drug technologies and delivery systems designed to address the chronic wound microenvironment. It also highlights preclinical models used to test drug treatments specific for the wound microenvironments of lower extremity diabetic, venous, ischemic, and burn wounds. We further discuss key differences between preclinical wound models and human chronic wounds that may impact successful translational drug treatment design.
- 18 April 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , A18
Submitting a successful NIH career development award for the vascular surgeon scientist
- 18 April 2024
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 79 (5) , A18
Submitting a successful NIH career development award for the vascular surgeon scientist
- Open Access
- 5 January 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
Submitting a successful National Institutes of Health career development award for the vascular surgeon scientist
- 5 January 2024
- Published by Elsevier in JVS-Vascular Insights
- Vol. 2
Open AccessSubmitting a successful National Institutes of Health career development award for the vascular surgeon scientist
- 19 May 2023
- Published by Elsevier in Surgical Clinics of North America
- Vol. 103 (4) , 745-765
Comprehensive Care of Lower-Extremity Wounds
- 19 May 2023
- Published by Elsevier in Surgical Clinics of North America
- Vol. 103 (4) , 745-765
Comprehensive Care of Lower-Extremity Wounds
- Open Access
Canonical Wnt Signaling Maintains Human Mesenchymal Progenitor Cell Multipotency During Adipose Tissue Development
Tissue development and repair throughout life depends on the availability of multipotent mesenchymal stem/progenitor cells capable of differentiating into specialized cell types. How an appropriately sized pool of such multipotent progenitors is maintained under varied signals for tissue growth and repair is unknown. We addressed this question by monitoring fate trajectories of human adipose tissue-derived multipotent progenitor cells using single-cell transcriptomics. Homogenous multipotent progenitors underwent two distinct fate trajectories rapidly upon induction of adipose differentiation– one toward the adipocyte fate, and the other towards a distinct, non-differentiated state characterized by up-regulation of canonical Wnt target genes. Upon isolation, this latter cell population was able to resume proliferation and display multipotency. Using canonical Wnt agonists and antagonists we find Wnt signaling is required for the maintenance of this multipotent pool under differentiation stimulus. In vivo , these cells are retained in adipose tissue developed from human multipotent progenitor cells in immunocompromised mice, and their transcriptomic signature is detected in human adult adipose tissue. Our study reveals a previously unrecognized mechanism for maintaining a functional pool of human mesenchymal progenitor cells under conditions of differentiation pressure, driven by Wnt signaling.
Open AccessCanonical Wnt Signaling Maintains Human Mesenchymal Progenitor Cell Multipotency During Adipose Tissue Development
Tissue development and repair throughout life depends on the availability of multipotent mesenchymal stem/progenitor cells capable of differentiating into specialized cell types. How an appropriately sized pool of such multipotent progenitors is maintained under varied signals for tissue growth and repair is unknown. We addressed this question by monitoring fate trajectories of human adipose tissue-derived multipotent progenitor cells using single-cell transcriptomics. Homogenous multipotent progenitors underwent two distinct fate trajectories rapidly upon induction of adipose differentiation– one toward the adipocyte fate, and the other towards a distinct, non-differentiated state characterized by up-regulation of canonical Wnt target genes. Upon isolation, this latter cell population was able to resume proliferation and display multipotency. Using canonical Wnt agonists and antagonists we find Wnt signaling is required for the maintenance of this multipotent pool under differentiation stimulus. In vivo , these cells are retained in adipose tissue developed from human multipotent progenitor cells in immunocompromised mice, and their transcriptomic signature is detected in human adult adipose tissue. Our study reveals a previously unrecognized mechanism for maintaining a functional pool of human mesenchymal progenitor cells under conditions of differentiation pressure, driven by Wnt signaling.
- Open Access
A Neurogenic Signature Involving Monoamine Oxidase-A controls Human Thermogenic Adipose Tissue Development
Mechanisms that control “beige/brite” thermogenic adipose tissue development may be harnessed to improve human metabolic health. To define these mechanisms, we developed a species-hybrid model in which human mesenchymal progenitor cells were used to develop white or thermogenic/beige adipose tissue in mice. The hybrid adipose tissue developed distinctive features of human adipose tissue, such as larger adipocyte size, despite its neurovascular architecture being entirely of murine origin. Thermogenic adipose tissue recruited a denser, qualitatively distinct vascular network, differing in genes mapping to circadian rhythm pathways, and denser sympathetic innervation. The enhanced thermogenic neurovascular network was associated with human adipocyte expression of THBS 4 , TNC , NTRK3 and SPARCL1 , which enhance neurogenesis, and decreased expression of MAOA and ACHE , which control neurotransmitter tone. Systemic inhibition of MAOA, which is present in human but absent in mouse adipocytes, induced browning of human but not mouse adipose tissue, revealing the physiological relevance of this pathway. Our results reveal species-specific cell type dependencies controlling the development of thermogenic adipose tissue and point to human adipocyte MAOA as a potential target for metabolic disease therapy.
Open AccessA Neurogenic Signature Involving Monoamine Oxidase-A controls Human Thermogenic Adipose Tissue Development
Mechanisms that control “beige/brite” thermogenic adipose tissue development may be harnessed to improve human metabolic health. To define these mechanisms, we developed a species-hybrid model in which human mesenchymal progenitor cells were used to develop white or thermogenic/beige adipose tissue in mice. The hybrid adipose tissue developed distinctive features of human adipose tissue, such as larger adipocyte size, despite its neurovascular architecture being entirely of murine origin. Thermogenic adipose tissue recruited a denser, qualitatively distinct vascular network, differing in genes mapping to circadian rhythm pathways, and denser sympathetic innervation. The enhanced thermogenic neurovascular network was associated with human adipocyte expression of THBS 4 , TNC , NTRK3 and SPARCL1 , which enhance neurogenesis, and decreased expression of MAOA and ACHE , which control neurotransmitter tone. Systemic inhibition of MAOA, which is present in human but absent in mouse adipocytes, induced browning of human but not mouse adipose tissue, revealing the physiological relevance of this pathway. Our results reveal species-specific cell type dependencies controlling the development of thermogenic adipose tissue and point to human adipocyte MAOA as a potential target for metabolic disease therapy.